One comment on “October Surprises, Part 2

  1. > China and Sinopharm … ask that the US consider the approval of China’s NMPA to be good enough evidence of the vaccine’s safety and effectiveness. How does the FDA react?

    The FDA currently seems to be under the thumb of Trump. I can’t see them giving China the benefit of the doubt before China makes that offer to dedicate half the doses to the US.

Comments are closed.